Business Context and Reporting Period
Company: Arrivent Biopharma, Inc. (AVBP)
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2026
Reporting Period: Single event date (March 17, 2026)
Business Context: The Company is an emerging growth company focused on biopharmaceutical development. This filing discloses upcoming scientific presentations regarding its drug candidates.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates regarding prior periods are disclosed in this filing. The report focuses solely on the announcement of future scientific presentations.
Outlook, Management Commentary, and Risks
- Scientific Presentations: The Company plans to present two preclinical posters at the 2026 AACR Annual Meeting.
- Candidate 1: Firmonertinib, an EGFR inhibitor.
- Candidate 2: ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC.
- Regulatory Disclosure: The information is furnished under Regulation FD (Item 7.01) and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific dates and location of the 2026 AACR Annual Meeting.
- Review the full text of the press release (Exhibit 99.1) for detailed preclinical data summaries.
- Monitor subsequent filings for any updates on the clinical development timelines for firmonertinib and ARR-002.
- Check the Company's latest 10-K or 10-Q for current cash runway and burn rate, as this 8-K does not contain financial data.